Literature DB >> 3052818

Psychotropic drug induced weight gain: mechanisms and management.

J G Bernstein1.   

Abstract

Most of the drugs commonly used in the treatment and prophylaxis of depression, mania, and psychotic illness have, as one of their prominent side effects, the ability to increase appetite, stimulate carbohydrate craving, and promote weight gain. These side effects are troublesome to patients, and frequently constitute a major reason for premature discontinuation of therapy. This review examines the relative likelihood of the occurrence of appetite stimulation and weight gain with various psychotropic medications. Potential mechanisms of these effects and strategies to minimize or avoid weight gain during pharmacotherapy of psychiatric illness are examined. Evidence suggests that those compounds, which either antagonize or downregulate serotonin receptors, are more likely to stimulate carbohydrate hunger and weight gain. Amitriptyline, chlorpromazine, mesoridazine, thioridazine, and lithium are most likely to produce weight gain. Compounds that have more pronounced serotonergic action, such as fluoxetine and fenfluramine, are more likely to decrease carbohydrate craving and promote weight loss.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052818

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

1.  Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.

Authors:  K I Melkersson; A L Hulting; A J Rane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 2.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

3.  Long-term continuous administration of a hydro-ethanolic extract of Synedrella nodiflora (L) Gaertn in male Sprague-Dawley rats: biochemical, haematological and histopathological changes.

Authors:  Patrick Amoateng; Samuel Adjei; Dorcas Osei-Safo; Believe Ahedor; Seidu A Mahmood; Benoit B N'guessan; Isaac J Asiedu-Gyekye; Alexander K Nyarko
Journal:  Ghana Med J       Date:  2016-09

4.  Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities.

Authors:  Charles T Nguyen; Jennifer A Rosen; Robert G Bota
Journal:  Prim Care Companion CNS Disord       Date:  2012-10-18

5.  Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Authors:  Carol E Koro; Donald O Fedder; Gilbert J L'Italien; Sheila S Weiss; Laurence S Magder; Julie Kreyenbuhl; Dennis A Revicki; Robert W Buchanan
Journal:  BMJ       Date:  2002-08-03

6.  Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial.

Authors:  Ganesh R Pawar; P Phadnis; A Paliwal
Journal:  ISRN Psychiatry       Date:  2012-03-14

7.  Obesity and weight gain in relation to depression: findings from the Stirling County Study.

Authors:  J M Murphy; N J Horton; J D Burke; R R Monson; N M Laird; A Lesage; A M Sobol
Journal:  Int J Obes (Lond)       Date:  2009-01-13       Impact factor: 5.095

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.